Announcements

Walgreens Specialty Pharmacy Limit Fulfillment

On behalf of Leadiant Biosciences, Inc., I’m writing to inform you that we are experiencing a product shortage of Cystaran® (cysteamine ophthalmic solution) 0.44%, of which we hope will be a short-term impact on the patient community. Effective Monday, July 17, Walgreens Specialty Pharmacy will limit fulfillment of all new and refill prescriptions for Cystaran eye drops, to a maximum of two bottles per patient. The goal is to maximize the number of patients who continue to have access to Cystaran while product at Walgreens is limited. This action is necessary to accommodate a product supply interruption that the manufacturer of Cystaran is currently experiencing. We anticipate strong interest in learning more about this issue and concern among the patient and caregiver community. Leadiant understands the cystinosis community relies on Cystaran eye drops and we are committed to working diligently with the manufacturer of Cystaran to determine a solution as soon as possible. We will continue to provide you with updates as new information becomes available.

Best regards,

Lesli King
Director of Marketing Leadiant Biosciences

Sigma Tau Pharmaceuticlas, Inc. is now Leadiant Biosciences, Inc.

On Rare Disease Day, February 28, 2017, Sigma Tau announced it will now be known as Leadiant Biosciences. Leadiant says they will continue the commitment to patient communities. Read the full press release.

2017 Seedcorn Funding Program

The Cystinosis Research Network has collaborated with Cystinosis Ireland and Cystinosis Foundation UK to provide funding for Principle Investigators around the world interested in studying Cystinosis.

Cystinosis Rare Disease Day Campaign

Cystinosis

World Rare Disease Day (WRDD) is February 28, 2017. The global event was created to raise awareness for rare diseases like Cystinosis and highlight the impact on patients’ lives.

Cystinosis Volunteer Opportunity

An Iowa-based non-profit, John Paul II Medical Research Institute (JP2MRI), is looking for Cystinosis patients. Their Rare Disease Program aims to find more treatments and cures for children and patients with rare diseases.

JP2MRI is currently creating a stem cell biobank of patients with rare genetic diseases. They are currently enrolling rare disease patients through a patient registry to ultimately obtain blood or tissue samples. Participation in this research program is entirely voluntary. Your medical information will NOT go to any outside third parties. The patient registry is kept secure and confidential consistent with HIPAA regulations.

JP2MRI is not conducting clinical trials at this time. For more information, visit: www.jp2mri.org

Cystinosis Scholarship Program

Up to $50,000 in scholarships now available!

Global Genes and Horizon Pharma have partnered to bring the Cystinosis community up to $50,000 in continued education scholarships. This includes but is not limited to: college, graduate school, vocational programs, and enrichment courses.

Individuals living with Cystinosis could qualify for up $5,000 per person in funding. The award can be used for current, future AND previously paid tuition.

Scholarships will be awarded on a rolling basis to those with a genuine need for educational assistance.

Learn more at https://globalgenes.org/HNCS/.

logo

CRN Newsletter Signup - Popup
  1. Stay up-to-date with the latest information from the Cystinosis Research Network by joining our email list.

  2. First Name
    Invalid Input
  3. Last Name
    Invalid Input
  4. You must enter a valid email.